Saccharomyces boulardii alleviates DSS-induced intestinal barrier dysfunction and inflammation in humanized mice

Recent clinical studies have demonstrated a beneficial effect of Saccharomyces boulardii (S. boulardii) in inflammatory bowel disease (IBD). However, the underlying mechanisms remain poorly defined. In this study, we investigated the modulating effect of S. boulardii on the intestinal microbiota in humanized mice with dextran sulfate sodium (DSS)-induced colitis. The mice were fed an S. boulardii-supplement diet for 16 days before DSS treatment. The results showed that feeding S. boulardii significantly ameliorated the colon damage and regulated inflammatory responses by modulating the cytokine profile. These changes were found to be associated with an altered microbiome composition and short-chain fatty acid (SCFA) metabolism. Further analysis demonstrated that S. boulardii-derived polysaccharides and polypeptides promoted the growth of certain probiotics and increased the microbial metabolite SCFAs levels. Overall, these findings demonstrated the role of S. boulardii as a potential gut microbiota modulator to prevent and treat IBD.

Automated summary

The beneficial effects of S. boulardii on inflammatory bowel disease have been shown in recent clinical studies. This study investigated how S. boulardii modulates the intestinal microbiota in humanized mice with colitis induced by DSS. Results indicated that S. boulardii alleviated colon damage, regulated inflammatory responses, and altered microbiome composition and SCFA metabolism, supporting its role as a potential gut microbiota modulator for IBD prevention and treatment.